CNS Drugs Have a Low Approval Rate
Applied Clinical Trials
TTC
Only one in 10 self-originated drugs targeting diseases of the central nervous system (CNS) that entered clinical testing between 2002 and 2007 were approved. As such, CNS drugs have a success rate that is half that of the overall clinical approval success rate. Drug developers face numerous challenges in developing treatments targeting complex chronic illnesses in CNS including very demanding protocol designs and substantially longer development and regulatory review times. The clinical phase through approval duration for CNS drugs, for example, was 32 months longer than that of non-CNS drugs. Mean clinical phase duration for CNS drugs was 40% longer and the regulatory review and approval duration was 13% longer. CNS drugs are also far less likely to receive priority review status: between 1996 and 2010, non-CNS drugs were two-and-a-half times more likely to receive a priority review rating from the US Food and Drug Administration. The CNS new product pipeline, however, is among the richest, accounting for 11% of all drug development projects worldwide and growing by 6% annually.
Phase transition probabilities for self-originated CNS drugs and the benchmark for all TAs (2002-2007).
—Tufts Center for the Study of Drug Development, http://csdd.tufts.edu.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
